Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026
Company Deals

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Fineline Cube Jun 5, 2026
Company Deals

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Fineline Cube Jun 5, 2026
Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Fineline Cube Jun 5, 2026
Company Drug

Haisco’s HSK16149 Accepted for Review by NMPA for Diabetic Neuropathic Pain

Fineline Cube Nov 9, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing...

Company Deals Digital

Cowell Health Partners with AstraZeneca to Enhance Cancer Care at CIIE

Fineline Cube Nov 9, 2022

Cowell Health has announced a partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) at the 5th...

Company Drug

Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance

Fineline Cube Nov 9, 2022

China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical...

Company Drug

Zhaoke Ophthalmology Enrolls First Patients for ZKY001 in Phase II Trials

Fineline Cube Nov 9, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Policy / Regulatory

CDE Seeks Public Feedback on New Drug Benefit-Risk Assessment Guidelines

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released the “New Drug Benefit-Risk Assessment Technical Guidelines,”...

Company Deals

Zhaoke Ophthalmology Licenses C&V Tech’s TONO-i Tonometer for Greater China

Fineline Cube Nov 9, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Policy / Regulatory

CDE Releases Draft Guidelines on New Drug Benefit-Risk Assessment

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released the “New Drug Benefit-Risk Assessment Technical Guidelines,”...

Company Deals

Insilico Medicine Partners with Sanofi for AI-Driven Drug Discovery

Fineline Cube Nov 9, 2022

Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company based in Hong Kong, has announced...

Policy / Regulatory

CDE Releases Guidelines on Pediatric Anti-tumor Drug Development

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released a Technical Guidelines document focused on “Clinical...

Company Deals

Pfizer Partners with CARD, CSAF, and PingAn Good Doctor at CIIE

Fineline Cube Nov 9, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based...

Company Deals

Pfizer China Partners with Alibaba Health for Disease Education at CIIE

Fineline Cube Nov 9, 2022

The 5th China International Import Expo (CIIE) saw US-based Pfizer’s China unit announce a partnership...

Company Deals

Adicon Partners with Illumina to Advance Oncology Detection Assay TSO 500

Fineline Cube Nov 9, 2022

China-based Adicon Holdings Limited has announced a strategic partnership with US-based Illumina (NASDAQ: ILMN) at...

Company Deals

Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure

Fineline Cube Nov 9, 2022

US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...

Company Deals

Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure

Fineline Cube Nov 9, 2022

US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...

Company Drug

MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial

Fineline Cube Nov 9, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in...

Company Drug

Zhifei Bio Initiates Global Study for Omicron-Delta COVID-19 Vaccine in Uzbekistan

Fineline Cube Nov 9, 2022

China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study...

Company Deals

Mainline Biosciences Raises RMB 100M in Series A Financing for Peptide Drugs

Fineline Cube Nov 9, 2022

Mainline Biosciences, a polypeptide drug developer based in Zhongshan, has reportedly raised close to RMB...

Company Deals

Jiangsu Trausim Raises RMB 100M in Series A Financing for Dental Implants

Fineline Cube Nov 9, 2022

China-based Jiangsu Trausim Medical Instrument Co., Ltd, a wholly-owned subsidiary of Fulong Holdings and focused...

Company Drug

Cyramza Prescribed in China for Advanced Gastric Cancer

Fineline Cube Nov 9, 2022

Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...

Company Deals

Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization

Fineline Cube Nov 9, 2022

German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based...

Posts pagination

1 … 616 617 618 … 678

Recent updates

  • Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate
  • China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development
  • Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform
  • Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells
  • SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Company Drug

Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.